NASDAQ:STSA - Satsuma Pharmaceuticals Stock Price, Forecast & News

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

Satsuma Pharmaceuticals (NASDAQ:STSA) issued its quarterly earnings data on Tuesday, November, 12th. The financial services provider reported ($2.26) EPS for the quarter, missing the consensus estimate of ($1.01) by $1.25. View Satsuma Pharmaceuticals' Earnings History.

Satsuma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Satsuma Pharmaceuticals.

3 brokers have issued 1-year target prices for Satsuma Pharmaceuticals' shares. Their forecasts range from $16.00 to $20.00. On average, they anticipate Satsuma Pharmaceuticals' share price to reach $18.00 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View Analyst Price Targets for Satsuma Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Satsuma Pharmaceuticals.

Press coverage about STSA stock has trended somewhat positive on Saturday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Satsuma Pharmaceuticals earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news articles about the financial services provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Satsuma Pharmaceuticals.

Some companies that are related to Satsuma Pharmaceuticals include PNC Financial Services Group (PNC), BB&T (BBT), SunTrust Banks (STI), M&T Bank (MTB), Fifth Third Bancorp (FITB), KeyCorp (KEY), First Republic Bank (FRC), Regions Financial (RF), Huntington Bancshares (HBAN), SVB Financial Group (SIVB), Zions Bancorporation NA (ZION), Commerce Bancshares (CBSH), Signature Bank (SBNY), East West Bancorp (EWBC) and BOK Financial (BOKF).

(STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

Satsuma Pharmaceuticals' lock-up period expires on Wednesday, March 11th. Satsuma Pharmaceuticals had issued 5,500,000 shares in its public offering on September 13th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Satsuma Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include TPG Group Holdings SBS Advisors Inc. (10.85%), Eventide Asset Management LLC (2.45%), Zimmer Partners LP (0.58%), Dean Capital Investments Management LLC (0.21%), Millennium Management LLC (0.20%) and Teacher Retirement System of Texas (0.06%). Company insiders that own Satsuma Pharmaceuticals stock include Group Holdings (Sbs) Advis Tpg, Louis F Centofanti and Rajeev M Shah. View Institutional Ownership Trends for Satsuma Pharmaceuticals.

STSA stock was bought by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Eventide Asset Management LLC, Zimmer Partners LP, Dean Capital Investments Management LLC, Millennium Management LLC and Teacher Retirement System of Texas. Company insiders that have bought Satsuma Pharmaceuticals stock in the last two years include Group Holdings (Sbs) Advis Tpg, Louis F Centofanti and Rajeev M Shah. View Insider Buying and Selling for Satsuma Pharmaceuticals.

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STSA stock can currently be purchased for approximately $13.92.

Satsuma Pharmaceuticals has a market capitalization of $241.87 million. Satsuma Pharmaceuticals employs 11 workers across the globe.View Additional Information About Satsuma Pharmaceuticals.

The official website for Satsuma Pharmaceuticals is http://www.satsumarx.com/.

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider can be reached via phone at 650-410-3200.